Welcome to visit Hefei Kangchuntang Pharmaceutical Co., Ltd!

中文版 中文版  |   英文版 英文版
Manager
OA Login

Contact Us

Hefei Kangchuntang Pharmaceutical Co., Ltd.
Address: No.13, Branch Road, Biomedical Park, High-tech Zone, Hefei City, Anhui Province
Telephone:86551-63830999/63673366

Anhui Provincial Committee and Provincial Government issue "Specific Measures for Promoting the Inheritance and Innovation Development of Traditional Chinese Medicine"

2020-08-19 10:24

Recently, the Anhui Provincial Committee and Provincial Government issued the "Specific Measures for Promoting the Inheritance and Innovation Development of Traditional Chinese Medicine", proposing 23 specific measures to promote the inheritance and innovation development of traditional Chinese medicine in seven aspects: providing TCM services covering the entire population and life cycle, continuously deepening TCM reform, optimizing and strengthening the modern TCM industry, strengthening the quality and safety supervision of TCM, accelerating the construction of TCM talent teams, promoting the inheritance, innovation, and open development of TCM, and ensuring measures.

National Medical Products Administration's Opinions on Further Strengthening the Drug Adverse Reaction Monitoring and Evaluation System and Capacity Building

2020-08-14 14:31

In recent years, significant progress has been made in the monitoring and evaluation of adverse drug reactions, adverse events related to medical devices, adverse reactions to cosmetics, and drug abuse (hereinafter collectively referred to as adverse drug reaction monitoring and evaluation). Regulations have been continuously improved, the monitoring and evaluation system has been gradually established, the quantity and quality of reports have steadily increased, risk control measures have become more mature, and international cooperation has continued to strengthen, providing strong support for drug regulatory work. At the same time, it must be acknowledged that shortcomings remain in China's current drug adverse reaction monitoring and evaluation work. The number of grassroots monitoring and evaluation institutions has decreased, there is a shortage of professional personnel, the monitoring information system is lagging, monitoring and evaluation capabilities urgently need to be improved, and funding is insufficient to meet the needs, which has to some extent affected the improvement of drug safety levels and the protection of public health rights. To fully implement the central government's requirements for strengthening drug safety in the new era, the following opinions are put forward on further strengthening the drug adverse reaction monitoring and evaluation system and capacity building.

State Council General Office Notice on Issuing Key Tasks for the Second Half of 2020 for Deepening Reform of the Medical and Health System

2020-07-31 10:48

In recent years, and especially since the Third Plenary Session of the 18th Central Committee of the Communist Party of China, China's medical and health system reform has continued to deepen, and the people's health status and the fairness and accessibility of basic medical and health services have continuously improved. Since the outbreak of the COVID-19 epidemic, the medical and health system has withstood the test and played an important role in winning the battle against COVID-19.

Notice on Issuing the Management Measures for Medical Consortiums (Trial Implementation)

2020-07-20 10:16

To further advance the tiered diagnosis and treatment system and build a high-quality and efficient medical and health service system, in accordance with relevant requirements such as the "Guiding Opinions of the General Office of the State Council on Promoting the Construction and Development of Medical Consortiums" (Guobanfa [2017] No. 32), and based on the experience of pilot programs for medical consortia (hereinafter referred to as medical consortia) construction in various places, the National Health Commission and the National Administration of Traditional Chinese Medicine have formulated the "Management Measures for Medical Consortiums (Trial Implementation)" to accelerate the construction of medical consortia and gradually achieve grid-based management of medical consortia networks.

Announcement (No. 13, 2020) of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on the Release of the Guiding Principles for the Management of Drug Clinical Trials During the Novel Coronavirus Pneumonia Epidemic (Trial)

2020-07-17 14:15

To standardize drug clinical trials in China during the COVID-19 epidemic and provide effective safety management measures, the Center for Drug Evaluation (CDE), under the direction of the National Medical Products Administration (NMPA), has developed the "Guiding Principles for the Management of Drug Clinical Trials during the COVID-19 Epidemic (Trial)" (see attachment).

Notice from the Office of the National Administration of Traditional Chinese Medicine on the Launch of the Performance Evaluation of Secondary and Tertiary Public TCM Hospitals in 2020

2020-07-10 15:21

To implement the requirements of documents such as the "Opinions of the General Office of the State Council on Strengthening the Performance Evaluation of Tertiary Public Hospitals" (Guobanfa [2019] No. 4) and the "Notice on Strengthening the Performance Evaluation of Secondary Public Hospitals" (Guoweiban Yi Fa [2019] No. 23), and to continuously promote the performance evaluation of national public TCM hospitals, the following notice is issued regarding the 2020 performance evaluation of secondary and tertiary public TCM hospitals.

National Medical Products Administration Announcement on Re-issuing Drug Registration Fee Standards (No. 75, 2020)

2020-07-03 10:56

In accordance with the "Regulations on Drug Registration Management" (Order No. 27 of the State Administration for Market Regulation), the "Notice on Re-issuing the Centrally Managed Administrative and Business Charges of the Food and Drug Supervision and Administration Departments" (Cai Shui [2015] No. 2), and the "Notice on Issuing the "Management Measures for Drug and Medical Device Product Registration Fees" (Development and Reform Price [2015] No. 1006), the National Medical Products Administration has formulated the "Drug Registration Fee Standards" and the "Implementation Rules for Drug Registration Fees", which are hereby announced and shall come into effect from July 1, 2020.

Notice of the National Healthcare Security Administration Office on Issuing the Detailed Grouping Scheme (Version 1.0) for Medical Security Disease Diagnosis Related Groups (CHS-DRG)

2020-06-18 14:14

Following the national pilot program for payment based on diagnosis-related groups (DRGs), and in order to implement the "three-step" goal of the pilot program and guide localities in standardizing DRG grouping work, our bureau has compiled the "Detailed Grouping Plan for Medical Insurance Diagnosis-Related Groups (CHS-DRG) (Version 1.0)" (hereinafter referred to as "CHS-DRG Detailed Grouping"), which is hereby issued to you, along with the following notice on related matters.

Public Notice Soliciting Opinions on the Draft Notice on Doing a Good Job in the Clinical Application Management of Antimicrobial Drugs Under the New Situation

2020-06-11 11:35

To implement the "Opinions on Strengthening Pharmaceutical Management in Medical Institutions and Promoting Rational Drug Use" and the "National Action Plan for Curbing Bacterial Resistance (2016-2020)", and to continuously improve the rational use of antimicrobial drugs, the National Health Commission, in conjunction with the current new work situation, has organized the drafting of the "Notice of the Office of the National Health Commission on Doing a Good Job in the Clinical Application Management of Antimicrobial Drugs under the New Situation (Draft for Comments)". Public comments are now solicited.

Notice from the Comprehensive Department of the National Medical Products Administration on Issuing the 2020 Medical Device Industry Standard Revision and Amendment Plan

2020-05-22 10:42

Notice from the Comprehensive Department of the National Medical Products Administration on Issuing the 2020 Medical Device Industry Standard Revision and Amendment Plan

< 123456 >